【摘要】 目的探讨75岁以上老年晚期非小细胞肺癌患者的化疗策略。方法总结29例具有明确病理学、细胞学证据的IIIB期、IV期75岁以上老年非小细胞肺癌患者的临床资料,紫杉醇联合卡铂治疗10例、紫杉醇单药治疗5例,不含紫杉醇联合方案治疗14例。29例中位化疗周期为1～6个周期。化疗结束后评价疗效和不良反应,并统计无进展生存期(PFS)和总生存期(OS)。结果10例接受紫杉醇+卡铂方案者,化疗周期为2～5个周期(中位3个周期),疗效均稳定,无进展生存期为2～10个月;不良反应主要为Ⅲ～Ⅳ度白细胞低下(6例)、贫血(5例)、外周神经毒性(1例)及口腔溃疡(1例),10例均出现Ⅱ度以上胃肠反应。5例接受紫杉醇单药方案者,均为部分缓解,无进展生存期为2～9个月;主要不良反应为Ⅲ～Ⅳ度白细胞低下(1例)、贫血(2例)、Ⅱ度胃肠道反应(3例)。14例接受不含紫杉醇联合化疗者,1例部分缓解,3例稳定,9例进展,无进展生存期为1～7个月;不良反应为Ⅲ～Ⅳ度白细胞低下(7例)、贫血(6例)、Ⅱ度的胃肠反应(12例)、重度乏力(4例)、合并感染(1例)。3组的总生存时间平均为5、8、6个月,1年生存率为0、40%、38.5%。结论对于75岁以上老年晚期非小细胞肺癌的化疗,应用紫杉醇单药治疗较联合方案更为安全有效。更多还原

【Abstract】 Objective To analyze the efficacy and survival rate of 1st line chemotherapy in elderly advanced non small cell lung cancer (NSCLC) patients older than 75 years old. Methods A total of 29 eligible patients with advanced NSCLC received paclitaxel alone or in combination with carboplatin or another chemctherapy without paclitaxel. The efficacy and adverse reactions were evaluated,PFS and OS were analyzed. Results Although the remission rate and the survival rate in the only paclitaxel group were better than the other two groups,there was no significant difference,even in side effects. Conclusions Only Paclitaxel would be a better treatment in elderly advanced NSCLC patients older than 75 years old,and it is worth to more clinical studies in future.更多还原